Top Page
Memphasys Ltd
(Sydney:MEM)
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Memphasys Ltd Business Overview & Revenue Model
Memphasys Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 526.92K | 526.92K | 60.00K | 15.37K | 27.15K | 211.48K |
| Gross Profit | 431.06K | 431.06K | -1.57M | -824.86K | -922.60K | -48.00K |
| EBITDA | -2.57M | -2.57M | -4.24M | -2.36M | -1.39M | -1.14M |
| Net Income | -4.94M | -4.94M | -4.44M | -3.40M | -2.08M | -1.49M |
Balance Sheet | ||||||
| Total Assets | 11.02M | 11.02M | 12.43M | 14.67M | 14.12M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 298.30K | 298.30K | 277.80K | 637.83K | 311.83K | 2.00M |
| Total Debt | 5.11M | 5.11M | 4.81M | 6.37M | 5.56M | 5.36M |
| Total Liabilities | 5.65M | 5.65M | 5.59M | 7.28M | 6.47M | 5.97M |
| Stockholders Equity | 5.37M | 5.37M | 6.84M | 7.38M | 7.65M | 8.61M |
Cash Flow | ||||||
| Free Cash Flow | -2.41M | -2.41M | -3.87M | -3.23M | -2.61M | -2.96M |
| Operating Cash Flow | -2.41M | -2.41M | -3.23M | -1.41M | 311.82K | 47.25K |
| Investing Cash Flow | -673.28K | -673.28K | -711.05K | -1.98M | -3.08M | -3.00M |
| Financing Cash Flow | 3.15M | 3.15M | 3.54M | 3.75M | 1.03M | 2.99M |
Memphasys Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
41 Neutral | AU$24.49M | -28.00 | -30.33% | ― | ― | ― | |
39 Underperform | AU$16.12M | -3.57 | -90.15% | ― | -93.83% | 20.00% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Memphasys Ltd Corporate Events
Memphasys Limited has disclosed a change in the securities interests of director Marjan Mikel, noting both direct and indirect holdings through entities associated with him. The filing details Mikel’s acquisition of 6,666,667 fully paid ordinary shares at $0.003 per share, along with a package of free attaching unlisted options and additional nil-cost alignment options with various exercise prices and expiries, indicating a material increase in his equity exposure and incentive-based alignment with the company’s future performance.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys has secured CE Mark approval under the European Union Medical Device Regulation for its Felix™ automated sperm selection system, allowing commercial sale and clinical use across the European Economic Area and other CE-recognising jurisdictions, and positioning the product as a globally deployable commercial platform. The certification immediately unlocks an estimated annual addressable market of more than €29 million in Europe alone, activates multi-year distribution and supply agreements in Europe and the MENA region worth over A$1.3 million in minimum contracted purchases, and supports the company’s transition into a revenue-scaling phase, with early cartridge orders, clinics prepared for immediate adoption, and additional regulatory clearances in India and Australia expected to follow under mutual recognition pathways.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has requested and been granted a trading halt on its shares on the Australian Securities Exchange from the open of trading on 24 December 2025, with the halt to remain in place until either the release of a pending market announcement or the commencement of normal trading on 30 December 2025. The company says the halt is needed to manage its continuous disclosure obligations while it prepares an announcement regarding a key regulatory milestone, signalling that a potentially material regulatory development is imminent for the business and its shareholders.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys has signed a five-year commercial supply agreement with Centro Fertilita Assistita (CFA) Italia, one of Italy’s largest private IVF groups, marking its first commercial contract in mainland Europe and a key step in its global rollout of the Felix sperm isolation system. The deal includes minimum purchase commitments of 7,500 Felix cartridges over the term, valued at about €525,000 (~A$925,000), with CFA already placing an initial order for 500 cartridges ahead of CE Mark approval, providing near-term revenue and validating demand for the technology and the company’s direct sales model. Leveraging CFA’s extensive network of IVF clinics in a large and growing Italian fertility market, the agreement establishes a pathway to recurring revenue, potential volumes beyond the contracted minimums, and broader European expansion once regulatory clearance is achieved.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has notified the market of the issue of a total of 25 million unquoted Alignment Options in three tranches (6.5 million, 8.5 million and 10 million) on 19 December 2025. These options, which are not quoted and are not intended to be quoted on the ASX, form part of previously announced transactions and indicate the company’s continued use of equity-based instruments to align incentives and support its longer-term capital and remuneration strategies.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has issued 1,666,667 unquoted options (MEMAX) exercisable at $0.011 and expiring on 5 November 2026, as notified to the ASX in a new Appendix 3G filing dated 19 December 2025. The options, which arise from previously announced transactions and are not intended to be quoted on the ASX, modestly expand the company’s pool of unquoted equity-linked securities and may have a dilutive effect for existing shareholders if exercised, while providing additional incentive or funding flexibility depending on their purpose and holders.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has applied for quotation on the ASX of 6,586,953 new fully paid ordinary shares under the code MEM. The newly issued securities, which stem from a previously announced transaction, will expand the company’s quoted share capital from 19 December 2025, potentially enhancing liquidity and broadening its investor base.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has applied to the ASX for quotation of 6,666,667 new fully paid ordinary shares under code MEM, with an issue date of 19 December 2025, pursuant to previously announced transactions. The move will expand the company’s quoted capital base, potentially enhancing liquidity in its stock and reflecting the progression of earlier capital or transaction arrangements previously disclosed to the market.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has received an early order for 500 Felix™ cartridges from its key Middle East partner, International Technical Legacy (ITL), ahead of the product’s CE Mark approval. This accelerated purchase highlights strong demand from ART clinics driven by direct clinical engagement and operational readiness initiatives. The order, valued between A$40,000 and A$75,000, reflects ITL’s confidence in the product and positions clinics for immediate deployment upon regulatory clearance, underlining the effectiveness of Memphasys’ direct-selling model in fostering adoption and showcasing its strategic alignment with clinic networks in high-growth regions.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited has announced a leadership restructure to support its shift towards a direct-selling global commercialization strategy for its Felix™ System. The restructure includes the redundancy of the CEO position and the departure of Dr. David Ali, with resources redirected to business development and commercial positions in priority markets. The company is preparing for the commercial rollout of the Felix™ System, with imminent CE Mark approval expected to unlock the European IVF market. Memphasys is implementing a direct-selling model to enhance customer engagement and market penetration, reallocating resources to support commercial and operational efforts outside Australia, particularly in the EU, MENA, and India. This strategic shift is aimed at ensuring capital discipline and aligning the organization with its core focus on widespread adoption of the Felix™ System.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Limited is advancing the commercialisation of its Felix™ sperm-selection device through a direct sales strategy in the Middle East, focusing on converting clinical interest into purchasing behavior and recurring revenue. The strategy includes direct engagement with IVF clinics in Qatar and the UAE, aiming to prepare them for immediate purchasing upon anticipated CE Mark approval in early 2026. This initiative, highlighted by a keynote address at the Middle East Fertility Society Conference, is expected to significantly expand Memphasys’ market presence and revenue potential in the region.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
Memphasys Ltd announced the results of its Annual General Meeting held on November 20, 2025. Several resolutions were passed, including the election of directors and the approval of issuing shares and options to various stakeholders. The outcomes of these resolutions are expected to influence the company’s strategic direction and stakeholder engagement, reflecting a focus on strengthening its governance and financial structure.
Memphasys Ltd, a company listed on the Australian Securities Exchange (ASX) under the ticker MEM, is focused on the commercialisation of its product, Felix. The company has released an investor presentation outlining its strategic focus on product development and commercialisation activities, with indicative timelines subject to change. This announcement highlights Memphasys’s commitment to advancing its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.
Memphasys Limited has undergone significant strategic realignment, focusing on the commercial success of its Felix™ system. The company has shifted from a traditional distributor model to engaging with partners for better market adoption and has implemented cost-saving measures to improve operational efficiency. Key achievements include securing initial orders from international partners and progressing towards CE Mark regulatory approval, expected in early 2026. These efforts have strengthened Memphasys’ governance and commercial pathways, positioning it as a leading fertility technology company.
Memphasys Limited has issued 33,333,333 fully paid ordinary shares at $0.003 per share to professional and sophisticated investors, as part of a placement announced in September 2025. This move is in line with the company’s strategy to scale production and establish the Felix ™ System as a global standard in sperm preparation for IVF, potentially enhancing its market position and operational efficiency.
Memphasys Limited has announced the application for the quotation of 33,333,333 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it signifies a strategic step in enhancing the company’s market presence and liquidity, potentially impacting its stakeholders by increasing the accessibility and tradability of its shares.
Memphasys Ltd has announced the issuance of 45,115,338 unquoted securities, specifically options expiring on November 5, 2026. This move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
Memphasys Ltd has announced the quotation of 180,460,810 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 10, 2025. This move is part of a previously announced transaction and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s financial flexibility and visibility in the market.
Memphasys Limited has successfully completed its Entitlement Offer, raising approximately $541,382.43 through the issuance of new shares and options. The funds will be used to advance the commercialization of the Felix™ System, including obtaining CE Mark approval for entry into European markets, scaling up manufacturing, and implementing marketing strategies in key regions. This financial move is expected to bolster Memphasys’s market positioning and facilitate the transition to recurring revenues, benefiting stakeholders by enhancing the company’s operational capabilities and market reach.
Memphasys Limited has completed a strategic shift to focus exclusively on the commercialisation of its Felix™ System, marking a transition from R&D to commercial execution. The company has achieved significant milestones, including a five-year distribution agreement in the MENA region, operational cost reductions, and strengthened governance, positioning itself for sustainable growth and increased market presence.
Memphasys Limited has signed a non-exclusive supply agreement with Andrology Center Coimbatore to expand its Felix™ System’s presence in the Indian market. This agreement marks a strategic shift to a go-direct commercial strategy, aiming to accelerate product adoption across over 200 IVF clinics in India. The partnership is expected to drive significant growth for Memphasys, with a minimum commitment of 1,800 Felix™ cartridges in the first year and a 50% increase in the second year. This move re-establishes Memphasys’ presence in India following regulatory changes and positions the company to capitalize on the rapidly expanding Indian IVF market, which is projected to grow significantly in the coming years.
Memphasys Limited announced changes in its board of directors, with Mr. Mathew Watkins appointed and Mr. David Ali ceasing as directors. The company acknowledged an administrative oversight in the timely filing of director interest notices but assured that current compliance arrangements are adequate. These changes are not expected to impact the company’s operations or compliance with ASX listing rules.
Memphasys Limited has secured a repeat order for 200 Felix ™ cartridges from the Nishitan ART Clinic Group in Japan, highlighting the growing adoption of its technology in the world’s largest IVF market. This order marks a significant step in Memphasys’ strategy to expand its direct commercial footprint in Japan, leveraging the country’s substantial self-pay IVF segment to drive revenue growth and enhance its market position.
Memphasys Ltd has announced the details for its 2025 Annual General Meeting (AGM), which will be held physically in Sydney. The company is adapting to modern communication methods by providing meeting materials online and encouraging electronic voting and communication, reflecting a shift towards more digital engagement with shareholders.
Memphasys Limited has announced several board changes as it pivots towards the commercialisation of its Felix ™ System. Dr. David Ali will step down as Executive Director to focus on his role as CEO, emphasizing operational execution as the company prepares for a global market rollout. Marjan Mikel has been appointed Chair of Commercialisation to oversee strategy and market expansion, while Mathew Watkins joins as an Independent Non-Executive Director, bringing extensive ASX experience to support the company’s growth and compliance efforts. These changes are aimed at strengthening Memphasys’ ability to execute its commercialisation plan, including the European launch post CE-Mark approval.
Memphasys Limited has dispatched its prospectus for a 1-for-6 pro-rata Non-Renounceable Entitlement Issue, aiming to raise approximately $1.12 million. The funds will support the commercialisation of the Felix™ System, including regulatory approvals for the European market, and provide working capital for corporate purposes. This initiative is expected to enhance Memphasys’s market position in the fertility treatment industry by advancing the adoption and production of its Felix™ System.
Memphasys Limited has announced a change in its company secretary, with Mr. Andrew Metcalfe concluding his role and Mr. Stefan Ross stepping in as the new Company Secretary effective 8 October 2025. Mr. Ross brings over 17 years of experience in governance and compliance, which will be instrumental as Memphasys progresses the commercialisation of its Felix™ System, aiming to establish it as a global standard in sperm selection.
Memphasys Ltd has announced an update regarding the proposed issue of securities, specifically a new class of options that will be unquoted. This update is part of their ongoing efforts to manage securities and align with ASX Listing Rules, potentially impacting their market operations and investor relations.
Memphasys Ltd has announced a proposed issue of securities, with a total of 118,564,120 securities to be issued, including various options and ordinary fully paid shares. This strategic move is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion in the reproductive biotechnology industry.
Memphasys Ltd has announced a proposed issue of securities, including 93,379,088 NRRI options and 373,516,350 ordinary fully paid shares, as part of a standard pro rata issue. This move is expected to impact the company’s financial structure and may influence its market positioning by potentially increasing capital for further development and expansion, thereby affecting stakeholders’ interests.
Memphasys Ltd has announced a pro-rata non-renounceable entitlement offer, allowing shareholders to acquire 1 share for every 6 shares held at $0.003 per share, along with 1 free new option for every 4 shares applied for. The company aims to raise approximately $1,120,549 through this offer, which includes secondary offers of new options to placement participants and Lynx. This move is part of Memphasys’ strategy to strengthen its financial position and potentially enhance shareholder value, although the securities offered are considered highly speculative.
Memphasys Limited has completed a placement of 257,500,000 ordinary shares at $0.003 per share, as announced on 1 October 2025. The company has issued these shares without disclosure under Part 6D.2 of the Corporations Act and has confirmed compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards.
Memphasys Ltd announced the application for quotation of 257,500,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to impact the company’s market presence by potentially increasing liquidity and investor interest.